Monoclonal gammopathy of clinical significance, abbreviated MGCS, describes a situation in which a clone of plasma cells in the bone marrow produces an abnormal, monoclonal immunoglobulin. Unlike monoclonal gammopathy of undetermined significance, or MGUS, in which the abnormal protein is a harmless laboratory finding, MGCS means the monoclonal protein is actively damaging tissue. Depending on the properties of the antibody, that damage can take many forms: nerve injury, kidney disease, skin changes, amyloid deposition or, as in the cases examined here, muscle disease. The concept, formalized in a landmark 2018 position paper in the journal Blood, implies something clinically crucial: treating the plasma cell clone itself, rather than only the damaged organ, can halt or reverse the disease.

The first of the two conditions, scleromyxedema-associated myopathy, arises in patients with scleromyxedema, a rare sclerosing skin disease characterized by widespread papular and waxy thickened lesions caused by mucin deposits in the dermis. Scleromyxedema is itself almost always linked to an IgG monoclonal gammopathy, and its systemic complications can include neurological and muscular involvement. Muscle weakness in these patients has been reported sporadically since the 1960s and 1970s, but the pathological picture has remained fragmentary. The second condition, VAMMGAS, was only recently characterized in the European Journal of Neurology by a team including several of the same French investigators. It combines progressive muscle weakness, muscle stiffness, vacuolar changes visible on muscle biopsy and a monoclonal gammopathy, but without the characteristic skin disease of scleromyxedema.

To test whether these entities belong to a single disease family, the researchers performed a detailed side-by-side comparison of three patients: two with SAM and one with VAMMGAS. They examined the clinical course, electrophysiological findings, light-microscopic histopathology and, critically, ultrastructural features seen under the electron microscope. They then placed their observations against the backdrop of the published literature on both disorders and on related monoclonal gammopathy-associated myopathies, including sporadic late-onset nemaline myopathy, amyloid myopathy and newly described glycogen storage myopathies linked to plasma cell clones.

The comparison revealed striking common ground. All three patients showed progressive weakness predominantly affecting the proximal muscles, those closest to the trunk, such as the hip and shoulder girdles. Electromyography, the technique that records the electrical activity of muscle fibers through a needle electrode, showed prominent pathological spontaneous activity in all cases. This finding, which reflects irritable, unstable muscle membranes, indicates that the muscle fibers themselves are being injured, and it helps distinguish these myopathic processes from pure nerve disorders. In both conditions, the muscle biopsy showed a myopathy with features suggesting that autophagy, the cellular housekeeping system that digests and recycles damaged components, was not working properly. Autophagy is essential for muscle health; when it falters, fibers accumulate abnormal vacuoles and material that they cannot clear, a pattern familiar to neuromuscular specialists from genetic disorders such as X-linked myopathy with excessive autophagy and from drug toxicities such as colchicine myopathy.

Alongside the autophagy signature, the biopsies carried clear fingerprints of immune activation. The muscle fibers abnormally expressed HLA class I molecules, the same antigen-presenting machinery that flags cells to the immune system, and deposits of C5b-9, the membrane attack complex of the complement cascade, were found on the sarcolemmal membranes of the fibers. These are the kind of findings typically seen in immune-mediated myopathies, where antibodies and complement attack muscle directly or mark it for destruction. In other words, the muscle in both diseases shows simultaneous evidence of a failed intracellular waste-disposal system and an active immune assault on the fiber surface, a combination that is unusual and diagnostically provocative.

There were differences, too, and they may prove just as informative as the similarities. By definition, SAM occurs in the context of scleromyxedema, and the researchers note that the skin disease may occasionally appear only after the muscle symptoms have begun, a sequencing that can delay diagnosis. VAMMGAS, by contrast, is defined by prominent muscle stiffness. The monoclonal protein also differs in a subtle but potentially meaningful way: in SAM the underlying gammopathy is most commonly IgG of the kappa light-chain type, whereas IgG lambda appears to be more frequent in VAMMGAS. On histology, inflammatory infiltrates, actual clusters of immune cells within the muscle tissue, seem to be more characteristic of SAM, while VAMMGAS leans more heavily toward the vacuolar, autophagy-impaired picture. The authors propose that the two diseases occupy different positions on a spectrum running between autophagy dysfunction at one pole and inflammation at the other, with individual patients landing somewhere in between depending on the biology of their particular monoclonal protein.

Why would a single abnormal antibody cause such a strange mixture of cellular pathology? The study does not deliver a definitive mechanism, but the framework it suggests is biologically plausible. Monoclonal immunoglobulins or their light chains are known to interfere with lysosomal function and autophagic flux in other MGCS-related diseases; in amyloid light-chain cardiotoxicity, for example, lysosomal dysfunction and impaired autophagy are established drivers of tissue damage. At the same time, immune complexes formed by monoclonal antibodies can activate complement, explaining the C5b-9 deposits on muscle membranes. Fibroblast growth factor 2 and transforming growth factor beta signaling have been invoked in the skin fibrosis of scleromyxedema, and TGF-beta is also known to epigenetically regulate autophagy, hinting at possible molecular bridges between the fibrosing, inflammatory and autophagic components of the syndrome.

The therapeutic implications may be the most consequential part of the work. Because both conditions appear to sit within the MGCS framework, they seem to respond to two complementary treatment strategies: immunomodulatory approaches, including intravenous immunoglobulin and plasma exchange, and clone-directed therapies that target the plasma cells producing the offending monoclonal protein. Intravenous immunoglobulin has long been a mainstay for the skin disease of scleromyxedema, and plasma exchange has been used successfully in refractory cases, while plasma cell-directed regimens have shown benefit in monoclonal gammopathy-associated scleromyxedema. Recognizing SAM and VAMMGAS as related MGCS manifestations gives clinicians a rationale for combining these approaches and for monitoring the monoclonal protein as a marker of disease activity, rather than treating the muscle in isolation with nonspecific immunosuppression.

For patients, the practical message is one of awareness. Unexplained progressive proximal weakness, especially when accompanied by muscle stiffness, thickened or waxy skin, or an abnormal protein band on serum electrophoresis, should prompt evaluation by a neuromuscular specialist and a hematologist together. The authors emphasize that recognizing the overlapping clinical, neurophysiological and histological features of SAM and VAMMGAS can shorten the diagnostic odyssey and open the door to treatments that address the root cause. With only a handful of cases described worldwide, much remains to be learned, and the researchers themselves frame their conclusions as hypothesis-generating rather than definitive. But the idea that a lone clone of antibody-producing cells can push muscle fibers simultaneously into autophagic failure and immune-mediated injury, and that this process can be caught and treated, marks a genuine step forward in the understanding of rare immune-muscle disease.

Subject of Research: Scleromyxedema-associated myopathy and VAMMGAS as monoclonal gammopathy-associated muscle diseases

Article Title: Scleromyxedema-Associated Myopathy and Vacuolar Myopathy with Monoclonal Gammopathy and Stiffness (VAMMGAS) as manifestations of Monoclonal Gammopathy of Clinical Significance (MGCS): a disease spectrum between autophagy dysfunction and inflammation

Article References: Nicoletti, T., Benveniste, O., Battistella, M., Mahevas, T., Arnulf, B., Stojkovic, T., Staedler, K., Maisonobe, T., Letournel, F., Romero, P., Malfatti, E., Vignon, M., Nadaj-Pakleza, A., Labella, B., Lacene, E., Brochier, G., Evangelista, T., & Leonard-Louis, S. (2026). Scleromyxedema-Associated Myopathy and Vacuolar Myopathy with Monoclonal Gammopathy and Stiffness (VAMMGAS) as manifestations of Monoclonal Gammopathy of Clinical Significance (MGCS): a disease spectrum between autophagy dysfunction and inflammation. Journal of Neurology, 273(10), Article 633. https://doi.org/10.1007/s00415-026-14169-2

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14169-2

Keywords: monoclonal gammopathy, MGCS, scleromyxedema, VAMMGAS, vacuolar myopathy, autophagy, muscle weakness, HLA class I, complement C5b-9, intravenous immunoglobulin, plasma exchange, neuromuscular disease

SPAID, which is freely accessible online at spaid.renlab.cn, organizes its evidence into two distinct levels. The first, a validated level, contains proteins carrying experimentally confirmed epitopes drawn from the Immune Epitope Database, supported by positive T-cell assays and major histocompatibility complex (MHC) ligand assays. The second, a proteomics-based level, aggregates disease-associated peptides and proteins identified through mass spectrometry from human patient samples, annotated with differential expression patterns, predicted immunogenicity scores, and functional features. This two-tier architecture allows researchers to distinguish between candidates backed by direct immunological experimentation and those flagged through high-throughput proteomic discovery that await laboratory validation.

The technical ambition behind SPAID is considerable. To capture non-canonical proteins, the team assembled candidate sequences from more than 660,000 non-coding RNA entries in RNAcentral and over 332,000 intronic sequences from the IntroVerse database. Each candidate was evaluated for coding potential using two independent algorithms, CPAT and CNCI, and only sequences passing both thresholds were retained. Open reading frames were then predicted with NCBI’s ORFfinder and translated into amino acid sequences, which were de-duplicated against the UniProt reference set. The result is a unified protein sequence space of 576,516 sequences, combining 42,444 canonical UniProt proteins with 534,072 non-canonical proteins, including 447,445 intron-derived and 86,627 ncRNA-derived candidates.

Onto this reference framework, the researchers mapped a wealth of experimental data. From 292 publications, they integrated T-cell and MHC ligand assay records, ultimately identifying 1,141 unique validated epitopes from 10 autoimmune diseases supported by 2,750 positive T-cell assay records, alongside 20,424 distinct epitopes from 21,566 positive MHC ligand assays across five diseases. In total, these experimentally supported epitopes mapped to 21,349 unique proteins, spanning 16,966 canonical, 1,681 intron-derived, and 2,702 ncRNA-derived proteins. The inclusion of non-canonical proteins at this level is particularly striking, as it suggests that proteins translated from non-coding RNAs and introns can serve as genuine immune targets in human autoimmunity.

The proteomics-based level is equally extensive. Drawing on public repositories including PRIDE, MassIVE.quant, jPOST, PeptideAtlas, and iProX, the team curated 675 human proteomic samples spanning 14 autoimmune diseases, stratified into 51 disease- and tissue-specific cohorts. Peptides were identified by searching tandem mass spectra against the unified sequence space using DIA-NN for data-independent acquisition datasets and MaxQuant for data-dependent acquisition, with stringent false discovery rate control of 1 percent at the peptide-spectrum match, peptide, and protein-group levels. This rigorous filtering was essential because non-canonical peptides carry a heightened risk of false-positive identification. The search yielded 176,363 mass spectrometry-identified peptides assigned to 26,085 disease-associated proteins, including 927 ncRNA-derived and 531 intron-derived proteins.

To transform raw protein identifications into biologically meaningful signals, SPAID performs differential expression analysis for each cohort, comparing disease samples against matched controls. Proteins were classified as disease-only detected, upregulated, downregulated, or other, and results across multiple cohorts were integrated using Robust Rank Aggregation to assess cross-study consistency. Across the 14 diseases, the platform identified 4,577 disease-only detected proteins, 2,571 significantly upregulated proteins, and 757 significantly downregulated proteins. Notably, the disease-only category included 193 ncRNA-derived and 28 intron-derived proteins, demonstrating that non-canonical translation products participate in disease-specific proteomic signatures rather than representing background noise.

One of the most consequential questions the team addressed was whether these non-canonical proteins are reproducible. In diseases supported by at least three independent proteomic cohorts, more than 40 percent of non-canonical proteins were repeatedly detected: 61.51 percent in psoriasis, 54.58 percent in systemic lupus erythematosus, 51.41 percent in Crohn’s disease, and 40.32 percent in rheumatoid arthritis. Even more striking, among the repeatedly detected proteins, expression patterns showed remarkable concordance, with 99.33 percent consistency in rheumatoid arthritis, 93.93 percent in lupus, and 87.72 percent in psoriasis. Cross-referencing with published literature revealed that only 1.10 percent of the 1,458 non-canonical proteins identified across the diseases had prior experimental support, meaning the overwhelming majority represent previously unrecognized translation products now documented at scale for the first time.

To pinpoint which of these proteins might actually provoke immune responses, SPAID incorporates an immunogenicity prediction pipeline. Every mass spectrometry-detected peptide was segmented into overlapping 8- to 14-mer fragments and evaluated for HLA class I presentation across 12 functional supertypes, integrating MHC binding affinity, peptide-MHC stability, and T-cell recognition probability. Candidates were then refined using PanPep, a machine-learning tool that estimates T-cell receptor interaction probabilities against a panel of 419 CDR3 sequences. Overall, 14.70 percent of the 176,363 detected peptides were classified as putatively immunogenic, mapping to 15,558 immunogenic proteins, or 59.64 percent of all disease-associated proteins in the database. Immunogenic candidates were strongly enriched among disease-only detected proteins, representing 69.24 percent of that subset, consistent with the idea that proteins elevated under inflammatory conditions feed the antigen-processing machinery that can expose sequestered self-determinants and cryptic epitopes.

By intersecting three features, disease-specific proteomic detection, predicted immunogenicity, and experimental epitope support, the team defined a high-confidence core set of 2,023 candidate autoantigens. The platform’s practical utility was then demonstrated in an independent rheumatoid arthritis cohort, where serum proteomics of five patients and five healthy controls identified 1,559 proteins, 132 of which were RA-associated. A two-step validation pipeline using SPAID recovered clinically established biomarkers such as gamma-interferon-inducible protein 16 (IFI16) and immunoglobulin mu heavy chain, while also flagging novel candidates. Nine proteins, including myosin-9 (MYH9), glutathione S-transferase P (GSTP1), and hemoglobin subunit gamma-1/2 (HBG1/2), harbored experimentally validated epitopes. APOA4, apolipoprotein A-IV, emerged as an entirely novel candidate with highly specific enrichment in RA samples and strong predicted immunogenicity but no prior literature link to the disease, illustrating how the database can surface unexpected therapeutic leads.

Beyond its scientific content, SPAID offers a polished web interface built on a MySQL backend with a Java-based server and interactive ECharts visualizations. Users can search by disease, tissue, or protein attributes, run BLAST searches against transcript, protein, and peptide datasets, and explore hierarchical gene, protein, and peptide pages featuring expression boxplots, volcano plots, 3D structural models from the Protein Data Bank or ColabFold, predicted post-translational modification sites generated with PTM-Mamba, and an MS/MS spectrum annotator. The authors are candid about limitations: immunogenicity predictions currently cover only HLA class I, omitting CD4 T-cell biology tied to HLA class II, and the underlying proteomic data skew toward accessible tissues such as blood and skin. Mass spectrometry, however stringent, cannot on its own prove functional translation or physiological epitope presentation. Positioned as a candidate discovery resource rather than a definitive catalog, SPAID nonetheless represents a foundational shift in how autoantigen research can be conducted, and its developers plan future expansions to include HLA class II data and broader tissue proteomics, potentially accelerating diagnostics and targeted therapies for millions of autoimmune patients.

Subject of Research: A comprehensive database for disease-specific autoantigen discovery in autoimmune disorders

Article Title: SPAID: a comprehensive database for disease-specific autoantigens in autoimmune disorders

Article References: Deng, S., Wei, F., Pang, Y., Zhang, L., Zhi, S., Chen, T., Zuo, Z., Ren, J., Xie, Y., & Luo, X. (2026). SPAID: a comprehensive database for disease-specific autoantigens in autoimmune disorders. Advanced Biotechnology, 4(2), Article 23. https://doi.org/10.1007/s44307-026-00117-8

Image Credits: AI Generated

DOI: 10.1007/s44307-026-00117-8

Keywords: autoimmune diseases, autoantigens, SPAID database, proteomics, non-canonical proteins, mass spectrometry, epitopes, HLA class I, immunogenicity prediction, rheumatoid arthritis, biomarker discovery, protein databases